Meeting
2023 ASCO Annual Meeting
Influence of adherence to adjuvant endocrine therapy in early breast cancer: Results from a large German real-world claims data analysis.
Authors
Dominik Dannehl
Department of Women's Health, Tuebingen University Hospital, Tuebingen, Baden-Wuerttemberg, Germany
Dominik Dannehl , Tobias Engler , Tjeerd Dijkstra , Raphael Gutsfeld , Alexandra von Au , Markus Hahn , Sabine Hawighorst-Knapstein , Ariane Chaudhuri , Markus Wallwiener , Armin Bauer , Sara Brucker , Stephanie Wallwiener , Andreas Daniel Hartkopf
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 551)
DOI
10.1200/JCO.2023.41.16_suppl.551
Abstract #
551
Poster Bd #
381
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Influence of ovarian function supression on quality of life in breast cancer survivors during adjuvant endocrine therapy.
First Author: Natalija Dedic Plavetic
Poster
2022 ASCO Annual Meeting
Adherence to adjuvant endocrine therapy assessed by data from prescription renewals and medical records from tamoxifen in Swedish patients with cytochrome P450 2D6 (CYP2D6) genotyped early breast cancer.
First Author: Linda Thoren
Poster
2017 ASCO Annual Meeting
Anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure.
First Author: Vivianne C. Tjan-Heijnen
Poster
2015 ASCO Annual Meeting
Final analysis of a randomized comparison of letrozole (Let) vs observation (Obs) as late reintroduction of adjuvant endocrine therapy (AET) for postmenopausal women with hormone receptor positive (HR+) breast cancer (BC) after completion of prior AET: ANZBCTG 0501 (LATER).
First Author: Nicholas Zdenkowski